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Abstract γ-Hydroxybutyric acid (GHB) is an endogenous
short-chain fatty acid popular as a recreational drug due to
sedative and euphoric effects, but also often implicated in
drug-facilitated sexual assaults owing to disinhibition and
amnesic properties. Whilst discrimination between endog-
enous and exogenous GHB as required in intoxication cases
may be achieved by the determination of the carbon isotope
content, such information has not yet been exploited to
answer source inference questions of forensic investigation
and intelligence interests. However, potential isotopic frac-
tionation effects occurring through the whole metabolism of
GHB may be a major concern in this regard. Thus, urine
specimens from six healthy male volunteers who ingested
prescription GHB sodium salt, marketed as Xyrem®, were
analysed bymeans of gas chromatography/combustion/isotope
ratio mass spectrometry to assess this particular topic. A very
narrow range of δ13C values, spreading from −24.81‰
to −25.06‰, was observed, whilst mean δ13C value of
Xyrem® corresponded to −24.99‰. Since urine samples and
prescription drug could not be distinguished by means of
statistical analysis, carbon isotopic effects and subsequent
influence on δ13C values through GHB metabolism as a
whole could be ruled out. Thus, a link between GHB as a raw
matrix and found in a biological fluid may be established,
bringing relevant information regarding source inference
evaluation. Therefore, this study supports a diversified scope
of exploitation for stable isotopes characterized in biological
matrices from investigations on intoxication cases to drug
intelligence programmes.
Keywords Gamma-hydroxybutyric acid . Gamma-
butyrolactone . Sodium oxybate . Isotope ratio mass
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Introduction
γ-Hydroxybutyric acid (GHB) is an endogenous short-
chain fatty acid found in mammalian brain tissues as a
metabolite of γ-aminobutyric acid (GABA), the primary
inhibitory neurotransmitter of the central nervous system
[1–3]. Biosynthesis also occurs through the peripheral
lactonase of γ-butyrolactone (GBL) and the alcohol
dehydrogenase of 1,4-butanediol (1,4-BD) into GHB upon
direct oral consumption (Fig. 1) [4]. Binding to GHB-
specific sites and GABAB receptors, this molecule
exhibits pharmacological properties sought after for
specific therapeutic purpose [5, 6]. Indeed, the sodium
salt of GHB, referred to as sodium oxybate, is used in the
treatment of narcolepsy, with cataplexy, and to help
relieve alcohol and opiate withdrawal syndromes [2, 6–
8]. Believed to increase the muscle mass due to a
stimulatory effect on growth hormone production, GHB
became popular amongst body builders as blended to
nutritional supplements [9, 10]. Owing to its sedative and
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euphoric effects, this compound quickly gained reputation
as a recreational drug due to its acknowledged use at
nightclubs and raves [11, 12]. Subsequently, implication
of GHB in drug-facilitated sexual assaults emerged,
resulting from a combination of heightened sex drive,
disinhibition and potential amnesia properties with an ease
of spiking in beverages as a colourless and odourless
liquid [13]. Whilst trends of both recreative and intoxi-
cating use remain fairly stable, various international
studies have reported severe intoxications and overdoses
over the last decade, but also significant progression of the
GBL consumption phenomenon [2, 14–19].
Therefore, discrimination between endogenous and
exogenous GHB in biological fluids, including blood and
urine, is often required in toxicological and forensic
investigations. However, source identification of this
compound is facing a number of challenges. One of the
key issues is the short half-life of GHB, with a plasma half-
life averaging <1 h, which translates into complete
elimination from blood and urine within 6 and 12 h,
respectively [20]. When considering the ordinary delay of
several hours between drug ingestion and sample
collection, along with the endogenous nature of GHB,
origin assessment of low urinary or blood concentrations
should be carefully interpreted. Accordingly, a general
agreement on a cutoff limit for the distinction between
endogenous and exogenous GHB is still prone to vast
discussions [21–25]. However, this question may be
addressed considering alternative biochemical markers. In
particular, determination of the carbon isotope composition of
this molecule has been proven promising to solve this issue
[26, 27]. Indeed, incorporation of 13C to the GHB molecule
through biosynthesis appears to differ from synthesis through
chemical precursors since the first reflects the C3 and C4
plant diet of an individual, whilst the latest corresponds to its
chemical precursors, namely GBL and 1,4-BD, originating
from petroleum extracts [28]. Thus, variations in the 13C/12C
ratio (δ13C values) allow discriminating between GHB of
endogenous and exogenous origins.
Beyond this problem, investigations on intoxication cases
and forensic drug intelligence could benefit from such
information for the assessment of the linkage between GHB
found in a biological sample and drug seizures. Actually, the
potential of stable isotope analysis for drug profiling is
valuable, as enlightened for cocaine, heroin, amphetamine-
based molecules, marijuana and GBL [28–37]. However, this
methodology has only been applied to the raw matrix at
present, and linking the aforementioned molecules found in
biological fluids and in seizure samples remains a promising
topic yet to be explored.
Thus, this work proposes to evaluate the likelihood of
isotopic fractionation due to metabolism in the body by
comparing δ13C values of prescription pharmaceutical
sodium oxybate, marketed as Xyrem®, with urinary GHB
of volunteers who ingested this specific prescription drug
during a study on sleep. In that respect, measurements were
achieved using an extensive sample cleanup procedure
followed by the conversion of GHB into GBL prior to
analysis by gas chromatography/combustion/isotope ratio
mass spectrometry (GC/C/IRMS) [26, 27].
Experimental
Reagents and chemicals
Methanol (≥99.9%), dichloromethane (≥99.9%) and acetic
acid (glacial, 100%) were purchased from Merck (Darmstadt,
Germany). Acetonitrile (≥99.7%) was obtained fromBiosolve
B.V. (Chemie Brunschwig, Basel, Switzerland) and hydro-
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chloric acid fuming (37%) and sodium chloride (>99.5%)
from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland). ε-
Caprolactone (≥99.0%, Lot no. 087K3521) was supplied by
Fluka (Buchs, Switzerland). Ultrapure water was produced
by a Milli-Q Gradient A10 water purification system
with a Q-Gard® 2 and a QuantumTM EX Ultrapure
organex cartridge purchased by Millipore Corp. (Bill-
erica, MA, USA). Helium (Quality 60, >99.9999%) and
carbon dioxide gas (quality 40, >99.99%) were obtained
from Carbagas (Domdidier, Switzerland). Oasis® MCX
cartridge 30 μm (6 cc, 150 mg) were supplied by Waters
(Milford, MA, USA) and Bond Elute SAX SPE car-
tridges 40 μm (3 mL, 500 mg) by Varian Inc. (Palo Alto,
CA, USA). GHB enzymatic assay kits were purchased
from Bühlmann Laboratories AG (Basel, Switzerland).
Sodium oxybate, trademarked as Xyrem® (Lot no.
A13870), was obtained from UCB-Pharma SA (Bulle,
Switzerland).
GHB urine specimens and prescription medication
Urine specimens were collected from 13 healthy male
volunteers, aged 20–26 years (mean age, 23.5±1.6 years),
participating in a study on effects on sleep of a sodium
oxybate oral preparation, trademarked as Xyrem®. Actually,
each subject ingested a sodium oxybate dose equivalent to
30 mg/kg body weight dissolved in 60 mL water twice during
the course of this study: once prior to sleep at 11 P.M. and once
prior to a 2-h nap at 3 P.M., with a minimum of 1-week
interval between both intakes. Urine samples were collected
shortly after waking up in the morning and between 9 and
10 P.M. after the nap, resulting in a 6- to 8-h delay after oral
consumption, and stored at −20 °C since collection until
GC-MS and GC/C/IRMS analyses. Endogenous levels of
GHB were assessed by the collection of urine specimens at
six different times over the treatment period and storage
under equal conditions. Xyrem® from the batch used for oral
administration was analysed as well.
Evidence on in vitro production of GHB in antemortem
urine samples has been highlighted as a process that is
dependent on storage conditions. Indeed, storage at ambient
temperature or refrigerated at 5 °C over a long period of
time can result in a significant increase of endogenous GHB
concentration [38, 39]. However, keeping urine samples
frozen at −20 °C has been reported as significantly reducing
this phenomenon to a minimum, even after up to 8 months
[40]. Thus, these were the preferred storage conditions for
this study.
Quantitative determination of GHB by enzymatic assay
Direct and quantitative determination of GHB in urine has
been performed by an enzymatic assay kit on the
Dimension® Xpand™ Plus Integrated Chemistry System
(Siemens Healthcare Diagnostics SA, Düdingen, Switzerland),
an automated chemistry and immunoassay analyser for
central laboratories. Reagents, calibrator and validator
vials were reconstituted and kept refrigerated at 4 °C
prior to analysis. Calibration was performed over the 10-
to 100-μg/mL range, with calibration standards at low,
medium and high concentration levels (k=3) and validator
standards (QC) at two concentration levels (k=2) analysed in
triplicate (n=3) each time. A calibration curve was built
using a linear regression whose suitability for quantification
purpose was verified by comparing concentration measure-
ments of QCs to confidence limits specified in the kit.
Eventually, a volume of 12 μL urine was used for each
enzymatic assay.
Conversion of prescription pharmaceutical GHB into GBL
In a 10-mL glass tube, 1 mL of 6 M hydrochloric acid was
added to 10 μg of Xyrem® prior to vortex mixing for ∼30 s.
Then, liquid–liquid extraction (LLE) was performed by
adding 1 mL dichloromethane and shaking the mixture by
inversion for 10 min using a rotator unit. After centrifugation
at 2,500 rpm for 5 min, the aqueous layer was transferred and
extraction was repeated once with 1 mL dichloromethane.
Eventually, the combined organic layer was evaporated in a
conical glass tube to ∼100 μL under a gentle stream of
nitrogen (20 psi) at 25 °C after the addition of 5 μL of 1 mg/
mL internal standard (IS) solution (ε-caprolactone in
dichloromethane).
Sample preparation
Urine sample cleanup is based on a method previously
published and shortened to our particular needs [26].
Considering the concentration of GHB, the volume of
urine aliquots was determined as follows:
Vurine ¼ 10GHBconcentration  mg; ð1Þ
with Vurine in millilitres and GHBconcentration in micrograms
per millilitre.
Then, urine aliquots were diluted up to a volume of
2 mL with water prior to centrifugation for 5 min at
2,500 rpm. Solid phase extraction (SPE) was performed on
an Oasis® MCX cartridge 30 μm (6 cc, 150 mg) previously
conditioned by successive addition of 2 mL methanol and
2 mL water. Elution of GHB was carried out with 2.5 mL of
methanol/0.1% formic acid in water (10:90, v/v). After
evaporation of the eluate to ∼0.5 mL under an air stream
(20 psi) at 50 °C, further purification was performed on a
Bond Elute SAX SPE cartridge 40 μm (3 mL, 500 mg).
Conditioning was achieved by successive addition of 2 mL
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methanol, 8 mL of 10% acetic acid and 2 mL water at a
flow rate of 0.5 mL/min. After loading of the urine extract,
interaction with the solid phase occurred for 15 min prior to
washing with 1 mL water, 1 mL water/methanol (50:50, v/v)
and 0.5 mL methanol at a flow rate of 0.5 mL/min. Elution
of the analyte was carried out with 3 mL of 10% acetic acid
in acetonitrile at a flow rate of 0.5 mL/min. After
evaporation of the eluate to dryness under a gentle air
stream (5 psi) at 50 °C, the residue was dissolved in 1 mL
of 6 M hydrochloric acid prior to vortex mixing for ∼30 s.
Then, LLE was performed with 1 mL dichloromethane for
10 min using a rotator unit. After centrifugation at
2,500 rpm for 5 min, the aqueous layer was transferred
and extraction was repeated once with 1 mL dichloro-
methane. Eventually, the combined organic layer was
evaporated to ∼100 μL in a conical glass tube under a
gentle stream of nitrogen (20 psi) at 25 °C after the addition
of 5 μL of 1 mg/mL IS solution.
GC/C/IRMS analysis
The carbon isotope measurements were performed on a
DeltaPlus XL IRMS system (ThermoFinnigan MAT, Bremen,
Germany) coupled to an Agilent 6890A Gas Chromatograph
(HP Analytical Division) via a Finnigan GC Combustion III
interface (ThermoFinnigan MAT). The samples were
injected using a CombiPal autosampler (CTC Analytics
AG, Zwingen, Switzerland). The mass spectrometer con-
sisted of an electron impact source held at a 3.0-kV
acceleration voltage for CO2 gas, a magnet and three
Faraday collectors for the measurement of the ions at
m/z 44, 45 and 46. Chromatographic separation was
achieved on a DB-17MS capillary column (30 m ×
0.25 mm i.d., 0.25-μm film thickness) from J&W
Scientific (Folsom, CA, USA). Helium was used as
carrier gas with a constant flow of 1.3 mL/min. The GC
injection port, combustion oven and reduction oven
temperatures were set to 280, 940 and 600 °C,
respectively. Standard on–off tests (reference carbon
dioxide gas pulses of 20-s duration) were introduced six
times during the chromatographic separation. Regarding the
analysis of the samples containing GBL and the IS, the
oven temperature was increased from 80 °C (5 min) to
240 °C at 20 °C/min, then to 300 °C at 30 °C/min, and
maintained at the final temperature for 2 min. The
volume of injection was 1 μL and the samples were
injected in the splitless mode (1.50 min). Oxidation of
the combustion reactor was performed over 1 h after
every batch of 20 samples.
The symbol δ is the standard notation for expressing
carbon isotope ratios. It is defined as the parts per
thousand deviation of isotopic compositions versus that
of Vienna Pee Dee Belemnite and is calculated according
to [41]:
1000
C)C/(
C)C/(C)C/(
‰/C
standard
1213
standard
1213
sample
1213
13
ð2Þ
Calibration of the reference gas was previously per-
formed using a mixture of three alkanes (Chiron AS,
Trondheim, Norway), C15 (n-pentadecane), C20 (n-eicosane)
and C25 (n-pentacosane), with δ
13C values of −30.22‰,
−33.06‰ and −28.21‰, respectively.
Acquisition and evaluation of the GC/C/IRMS data were
performed with the ISODAT 2.5 software (ThermoFisher
Scientific, Bremen, Germany).
GC-MS analysis
Prior to GC/C/IRMS analysis, identification of the substance
was ensured by GC-MS chromatographic retention time and
by measurement of the full EI-MS spectrum between m/z 40
and 300. The diagnostic ions selected for the identification of
each compound were the following: GBL (m/z 56, 86 and
42) and ε-caprolactone (m/z 55, 75, 84 and 114).
GC-MS analysis was performed on a Hewlett-Packard
5890 Serie II Plus chromatograph (HP Analytical Division,
Waldbronn, Germany) equipped with a HP 7673 autosampler
and coupled with a HP 5971 mass selective detector. GC
separation was achieved on a DB-17MS capillary column
(30 m×0.25 mm i.d., 0.25-μm film thickness) from J&W
Scientific. Helium was used as carrier gas with a constant flow
of 0.8mL/min and at the initial column head pressure of 15 psi.
For a robust identification of the target compounds, the GC
operating conditions were identical to GC/C/IRMS analysis.
Identification criteria
Identification criteria were defined according to a technical
document addressing this particular topic [42]. The chro-
matographic retention time (tR) tolerance window must be
within ±1% of the retention time of the reference material
analysed in the same batch. Concerning full EI-MS experi-
ments, at least two diagnostic ions are required, with the
relative intensity of any of the ions not differing by more
than 20% from that of the quality control material. A
signal-to-noise ratio >3 must also be considered.
Data treatment and analysis
The δ13C values were analysed statistically using S-PLUS®
7.0 for Windows. For distribution testing, a Kolmogorov–
Smirnov test of normality has been employed. Equality of the
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variances was assessed using a Levene test. Then, statistical
differences among samples were tested using the two-sample
t test, with p<0.05 considered statistically significant.
Results and discussion
Quantitative determination of GHB in urine by enzymatic
assay
Quantification by enzymatic assay has been favoured for
the reason that virtually no sample cleanup was required,
providing a high throughput particularly suitable for use as
a screening procedure. Indeed, such method allowed
targeting samples of interest in a rapid and straightforward
fashion. Noteworthy is that endogenous levels of GHB in
urine specimens collected at six different times over the
treatment period and reliability of storage conditions could
be assessed simultaneously along with this single batch of
analyses. Also, storage condition effects were limited as this
procedure allowed avoiding an additional freeze and thaw
cycle before urine extraction for compound identification and
isotopic measurements. Actually, this simple and fast quan-
tification method could be followed by a sample preparation
for GC/MS and GC/C/IRMS analyses within ∼1 h after
thawing of the urine specimens.
A concentration range comprising expected urinary
levels of both endogenous and exogenous GHB was
initially determined, with consideration of the performance
characteristics described in technical notes supplied with
the enzymatic assay kit. Thus, calibration was performed
over the 10- to 100-μg/mL range using calibrators at the
10-, 50- and 100-μg/mL concentration levels (k=3)
analysed in triplicate (n=3). Due to the linear response,
unweighted linear least-squares regression was chosen for
quantification purpose, with R2 corresponding to the
calibration curve being >0.99. Also, the suitability of direct
quantification of GHB in urine over the assay range was
established as the concentration values obtained for
calibration standards and standard deviations (SD) met the
guidelines specified in the aforementioned technical notes.
Also, samples exceeding the upper limit of quantification
were diluted 1:10 (v/v) with 0.9% sodium chloride solution,
as indicated by the manufacturer, and concentration values
were multiplied by 10.
Following quantification, urine specimens of interest for
further extraction and isotopic measurement were reduced
down to nine samples originating from seven subjects.
Indeed, in order to avoid more extensive purification steps
prior to IRMS measurements and to support the exogenous
origin of GHB found in urine, only samples with a
concentration above 20 μg/mL were selected (Table 1).
Noteworthy is that a few volunteers presented levels of
GHB lower than 10 μg/mL even after treatment with
Xyrem®, which may be explained by the short half-life of
this substance joint to a longer delay before urine collection
due to a prolonged sleep. Additionally, endogenous GHB in
urine specimens collected over the treatment period was not
detected. This ensured that subjects involved in this study
did not suffer from 4-hydroxybutyric aciduria, which would
result in naturally elevated endogenous levels of GHB [43,
44], and also excluded potential in vitro production issues.
Identification of GBL by GC/MS analysis
GC/MS analysis of Xyrem® and urine specimens allowed
the identification of target compounds and suitability
assessment for subsequent isotopic measurements. Satisfac-
tory sample cleanup was achieved for eight of the nine
samples, corresponding to six of the seven volunteers.
Indeed, identification criteria were met for GBL and ε-
caprolactone, with adequate chromatographic resolution
and complete conversion of GHB into GBL (Fig. 2), except
for one sample due to a co-eluting compound. Whilst the
nature of that molecule could not be clearly identified, an
exogenous origin may be hypothesized as there was no
previous observation of this compound in urine extracts,
even in trace amount. Thus, the latter was not submitted to
Type Subject Concentration (μg/mL) δ13C (‰) SD (‰)
Urine specimen 1 86.9 −24.97 0.06
76.5 −24.81 0.23
2 168.6 −24.92 0.08
97.4 −24.92 0.13
3 33.3 −25.02 0.20
4 22.6 −25.05 0.12
5 39.6 −25.06 0.25
6 35.5 −24.89 0.23
Standard Xyrem® −24.99 0.02
Table 1 Quantification of GHB
by enzymatic assay and carbon
isotopes determination in urine
specimens of interest by GC/C/
IRMS (n=8)
Source inference of exogenous GHB administered to humans 1109
IRMS analysis. Also, Xyrem® was found to be of excellent
purity.
Isotope measurements of GBL in urine by GC/C/IRMS
Conversion of GHB into GBL was favoured over conven-
tional derivatization with di-TMS in order to avoid the
addition of carbon atoms to the molecule [26, 45]. Indeed,
subsequent calculation of a correction factor accounting for
this phenomenon is necessary, resulting in δ13C values with
a larger SD [27]. Alternatively, conversion into GBL leads
to the loss of a molecule of water, with no influence on
carbon atoms attached to the original molecule of GHB.
Thus, translation of isotopic measurements of GBL into
δ13C values for GHB is straightforward.
Each sample preparation was spiked with ε-caprolactone, a
molecule very close in structure to GBL and displaying a
slightly different chromatographic retention. Potential mass
discrimination during the course of GC/C/IRMS analysis was
tested with ε-caprolactone serving as internal standard [28].
The reproducibility of isotopic measurements was assessed
accordingly, relying on the δ13C value of the IS calibrated
previously to this study (mean δ13C value=−23.40‰, SD=
0.21‰, n=30), using a 95% confidence interval as a run
acceptance criteria. Also, the stability of the system was
evaluated introducing reference carbon dioxide gas pulses
(20-s width) six times during the chromatographic separa-
tion, and pulses at 420 and 690 s were used to normalize
δ13C values (Fig. 3).
Prior to the isotopic measurements of urine specimens, the
linear response of the IRMSwas defined by injecting different
amounts of GHB converted into GBL from Xyrem®. Indeed,
the accuracy of the carbon isotopic ratio determination may be
significantly affected when the signal intensity is outside the
linearity range [46]. Thus, increasing quantities of GBL from
10 to 100 ng were injected, resulting in signal intensities
ranging from 389 to 4,432 mV, respectively. A linear
response was observed, as demonstrated by the stable δ13C
values (0.03‰ per millivolt) obtained.
Each urine sample was extracted in triplicate, and the
isotopicmeasurements of GHB are summarized in Table 1. The
δ13C values determined in this study range from −24.81‰
to −25.06‰, with relatively small deviations (SD<0.26‰).
The stability of IRMS measurements during the chromato-
graphic separation proved satisfying, as verified by the
standard on–off tests (mean δ13C value=−28.50‰, SD=
0.10‰, n=162 for six reference carbon dioxide gas pulses).
Likewise, reproducible δ13C values were collected for the IS
(mean δ13C value=−23.38‰, SD=0.19‰, n=27), with every
carbon isotope ratio comprised in the confidence interval
previously established (two-sample t test).
Noteworthy is that the distribution of δ13C values did not
show significant deviation from the isotopic values and
related SD of Xyrem® (mean δ13C value −24.99‰, SD=
0.02‰), as revealed by statistical tests. Indeed, equality of
the variances was verified using a Levene test and statistical
differences among urine specimens were ruled out by the
two-sample t test, with p<0.05 considered statistically
significant. Thus, metabolism of GHB did not induce a
significant carbon isotopic fractionation, as reported for
each of the six subjects.
Several pharmacokinetic studies described the conver-
sion of GHB to succinic semialdehyde and further to
succinate prior to entering into the Krebs cycle as the major
ε-caprolactone
GBL
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Fig. 2 GC-MS chromatogram
of a urine specimen containing
GHB at a concentration of
100 μg/mL and ε-caprolactone
at 50 μg/mL
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metabolic pathway, along with other minor metabolic
routes (Fig. 1) [8, 47, 48]. Due to this extensive hepatic
metabolism, <1% of the dose is excreted unchanged in
urine. Thus, verifying whether the carbon isotopic compo-
sition of this small amount of GHB recovered in urine
displayed variations with respect to the original pharma-
ceutical preparation was a crucial point. Indeed, reduction
of GHB into succinic semialdehyde by GHB dehydroge-
nase may lead to carbon isotopic fractionation due to the
kinetic isotope effect. Considering such effect, the reaction
rate of 13C-enriched isotopologues is known to be slower in
bond making or breaking chemical processes [49, 50].
Therefore, the small fraction of GHB found unchanged in
urine may potentially exhibit 13C enrichment compared to
the isotopic signature of the original dose administered to
the subjects. Also, renal reabsorption and metabolic
clearance of GHB could be hypothesized as an additional
source of carbon isotopic fractionation. However, determi-
nation of the carbon isotope ratio for each of the six
subjects did not highlight variations in the isotopic
composition through GHB metabolism as a whole. Ac-
cordingly, the potential sources of carbon isotopic fraction-
ation previously mentioned should not significantly affect
the δ13C values.
Our findings tend to demonstrate the possibility of
connecting GHB in biological samples and this substance
as a prescription or illicit drug by means of carbon isotope
determination. Noteworthy is that Xyrem® quantity admin-
istered to the volunteers corresponded to an average dose
for recreational use, which is significantly less than both
therapeutic and intoxicating doses. Therefore, the method-
ology applied in this study could be used at ease with
higher urinary concentrations of GHB. Such findings would
be very valuable when investigating intoxication cases and
in support of drug intelligence as they may fill the gap
between the raw matrix and biological fluids with valuable
information. Indeed, corresponding carbon isotope contents
would allow linking drug seizures to urine specimens, and
by extension drug traffickers to individuals charged with
substance abuse felony or suspicious individuals to drug
poisoning victims. This would bring an additional level of
evidence to tackle the aforementioned issues of forensic
interest. In addition, considering the increasing popularity
of GBL consumption, such studies could be followed up by
the assessment of metabolism influence on the carbon
isotopic profile of GBL excreted as GHB in biological
fluids.
Conclusion
Determination of the carbon isotope content of GHB by
GC/C/IRMS, performed with a previously published
method [26], was applied to eight urine specimens of six
healthy male volunteers who ingested pharmaceutical
GHB sodium salt, known as sodium oxybate and trade-
marked as Xyrem®, as part of a study on sleep. A very
limited range of δ13C values, from −24.81‰ to −25.06‰,
was observed, corresponding to the carbon isotopic values
of Xyrem® (mean δ13C value = −24.99‰) used for
treatment. Since urine samples and prescription drug could
not be discriminated by means of statistical analysis,
metabolism of GHB demonstrated no significant influence
on δ13C values.
This study provides a baseline for further studies and
for the exploitation of stable isotopes characterized in
biological matrices in both intoxication cases brought to
court and drug intelligence programmes. Indeed, source
inference subsequent to carbon isotope determination
appears achievable as highlighted by the link established
between GHB as a raw matrix or found in a biological
fluid. In addition, such studies may be extended to GBL,
a chemical precursor of increasing interest amongst
substance users, to assess potential isotopic fractionation
related to its metabolism prior to excretion as GHB in
biological fluids.
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